Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Quality in Covance

Record revenue and earnings are typically music to investors' ears: not so this time around for Covance (NYSE: CVD  ) . Since reporting its third-quarter results late last Wednesday, the drug development services outfit's stock is down 12%. For long-term investors, though, this company should stay on the radar.

Covance turned in net revenue of $341.5 million for the quarter, up 15.6% versus the same period last year. After factoring out a tax gain, earnings per share were $0.55, up 23.6% year over year (when stock options are removed from the equation). As for operating margin, it hit 14.4%, which was lower than the 14.9% reported in last year's third quarter. Still, after adjusting last year's operating earnings for new stock-related compensation rules, margin actually rose 90 basis points year over year.

Admittedly, Covance's breakneck growth does appear to be moderating. While a 23.6% increase in earnings is nothing to sneeze at, the firm sported a 30% rise in earnings in both the first and second quarters. Still, no cause for panic, Fools.

After all, Covance's current backlog of $2 billion is approaching twice the roughly $1.2 billion in revenue the firm reported last year. Although the company typically doesn't break out its client list, the mass of its backlog suggests that both smaller drug makers and larger firms like Eli Lilly (NYSE: LLY  ) and Pfizer (NYSE: PFE  ) are flocking to the development services firm.

In addition, Covance is likely to have more capacity next year, which should help fatten the bottom line. Capital expenditures this year are expected to be between $130 million and $140 million. This is down from the $153 million expended in 2005, but well above expenditures in 2004 and 2003.

Covance may be settling into a stride after a long sprint. But given its massive backlog and innovative deal making, the drug development services outfit is positioned to keep up a respectable pace.

For more on Covance, check out these stories:

Eli Lilly is anIncome Investorpick, while Pfizer is anInside Valueselection.

Fool contributor Brian Gormandoes not own shares in any of the companies mentioned.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 516809, ~/Articles/ArticleHandler.aspx, 10/25/2016 10:22:55 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
CVD.DL $0.00 Down +0.00 +0.00%
Covance CAPS Rating: *****
LLY $77.75 Up +0.18 +0.23%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.28 Up +0.15 +0.47%
Pfizer CAPS Rating: ****